Publikationen

2013

89 Albers C, Leischner H, Verbeek M, Yu C, Illert AL, Peschel C, von Bubnoff N, Duyster J.  The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD(+) AML but retains in vitro sensitivity to PKC412 and Sunitinib.  Leukemia. 2013;27(6):1416-8.

88 Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, Koehler R, Muckenthaler MU, Kulozik AE NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.  Haematologica. 2013 Jun;98(6):928-36. doi: 10.3324/haematol.2012.073585. Epub 2013 Jan 24.

87 Bauer RC, Sanger J, Peschel C, Duyster J, von Bubnoff N.  Sequential inhibitor therapy in CML: In vitro simulation elucidates the pattern of resistance mutations after second and third line treatment.  Clin Cancer Res. 2013;19(11):2962-72.

86 Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE.  Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.  Blood. 2013;121:2289-2300.

85 Dörge, P., Meissner, B., Zimmermann, M., Möricke, A., Schrauder, A., Bouquin, J.P., Schewe, J.P., Harbott,J., Teigler-Schlegel, A., Ratei, R., Ludwig, W.D., Koehler, R., Bartram, C.R., Schrappe, M, Stanulla, M., Cario, G.  IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.  Haematologica. 2013, 98:428-32.

84 Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TW, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, and Kirschner-Schwabe R.  Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.  Leukemia 2013 Feb;27(2):295-304. doi: 10.1038/leu.2012.155. Epub 2012 Jun 13.

83 Lee SG, Cho SY, Kim MJ, Oh SH, Cho EH, Lee S, Baek EJ, Choi JH, Bohlander SK, Lode L, Richebourg S, Yoon HJ, Marschalek R, Meyer C, Park TS.  Genomic breakpoints and clinical features of MLL-TET1 rearrangement in acute leukemias.  Haematologica. 2013;98:e55-e57.

82 Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J.  Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study.  J Clin Oncol. 2013;31:1172-1181.

81 Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.  Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.  Leukemia. 2013;27:353-61.

80 Schoofs T, Rohde C, Hebestreit K, Klein HU, Göllner S, Schulze I, Lerdrup M, Dietrich N, Agrawal-Singh S, Witten A, Stoll M, Lengfelder E, Hofmann WK, Schlenke P, Büchner T, Hansen K, Berdel WE, Rosenbauer F, Dugas M, Müller-Tidow C. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.  Blood. 2013 Jan 3;121(1):178-87.

79 Sigl M, Spoerl S, Schnittger S, Meissner J, Rummelt C, Peschel C, Duyster J, Ho AD, von Bubnoff N. Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.  Blood Cancer J. 2013 Mar 8;3:e104. doi: 10.1038/bcj.2013.3.

2012

78 Attarbaschi, A., Morak, M., Cario, G., Cazzaniga, G., Ensor, H.M., te Kronnie, G., Bradtke, J., Mann, G., Vendramini, E., Palmi, C, Schwab, C., Russell, L.J., Schrappe, M., Conter, V., Mitchell, C.D., Strehl, S., Zimmermann, M., Pötschger, U.,  Harrison, C.J., Stanulla, M., Panzer-Grümayer, R., Haas, O.A., Moorman, A.V. on behalf of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Berlin-Frankfurt-Münster (BFM) Study Group and National Cancer Research Institute (NCRI)-Children's Cancer and Leukemia (CCLG) Study Group.  Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukemia: A comparative analysis of the AIEOP-BFM and UK NCRI-CCLG Study Groups.  Br J Haematol. 2012, 158:772-7.

77 Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MWM, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L.  Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin-remodeling and splicing.  Blood. 2012;120:e83-92.

76 Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K, for the AML CG study group.  Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.  Ann Hematol. 2012;91:1051-1063.

75 Ellinghaus, E., Stanulla, M., Richter, G., Ellinghaus, D., te Kronnie, G., Cario, G., Cazzaniga, G., Horstmann, M., Panzer Grümayer, R., Cavé, H., Trka, J., Cinek, O., Teigler-Schlegel, A., ElSharawy, A., Häsler, R., Nebel, A., Meissner, B., Bartram, T., Lescai, F., Franceschi, C., Giordan, M., Nürnberg, P., Heinzow, B., Zimmermann, M., Schreiber, S., Schrappe, M., Franke, A. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia. 2012, 26:902-9.

74 Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.  RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.  Haematologica. 2012;97:1909-1915.

73 Greif PA., Dufour, A., Konstandin, N.P., Ksienzyk, B., Zellmeier, E., Tizazu, B., Sturm, J., Benthaus, T., Herold, T., Yaghmaie, M., Dörge, P., Hopfner, K.P., Hauser, A., Graf, A., Krebs, S., Blum, H., Kakadia, P.M., Schneider, S., Hoster, E., Schneider, F., Stanulla, M., Braess, J., Sauerland, M.C., Berdel, W.E., Büchner, T., Woermann, B.J., Hiddemann, W., Spiekermann, K., Bohlander, S.K.  GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.  Blood. 2012, 120:395-403.

72 Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 2012 Dec 27. [Epub ahead of print]
 
71 Kowarz E, Dingermann T, Marschalek R Do Non-Genomically Encoded Fusion Transcripts Cause Recurrent Chromosomal Translocations?  Cancers 4, 1036-1049.

70 Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TWL, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, Kirschner-Schwabe R.  Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.  Leukemia. 2013 Feb;27(2):295-304. doi: 10.1038/leu.2012.155. Epub 2012 Jun 13.

69 Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.  SRC is a signaling mediator in FLT3-ITD but not in FLT3-TKD positive AML.  Blood. 2012 Apr 26;119(17):4026-33. doi: 10.1182/blood-2011-07-365726. Epub 2012 Mar 12.

68 Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C.  High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.  Blood. 2012;120:2118-2126.

67 Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S, Krentz S, Cario G, Kasper D, Schmitt K, Russell LJ, Pötschger U, Stanulla M, Eckert C, Mann G, Haas OA, Panzer-Grümayer R.  Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.  Blood. 2012, 120:5134-42.

66 Mulaw MA, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK.  CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.  Leukemia. 2012 May;26(5):1012-9. doi: 10.1038/leu.2011.307. Epub 2011 Nov 8.
 
65 Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO.  Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.  Cell. 2012 Jan 20;148(1-2):59-71.                                                                             
 
64 Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.  Blood. 2012 Mar 1;119(9):2114-21.                                                                          
 
63 Schiesser S, Hackner B, Pfaffeneder T, Müller M, Hagemeier C, Truss M, Carell T.  Mechanism and Stem-Cell Activity of 5-Carboxycytosine Decarboxylation Determined by Isotope Tracing.  Angew Chem Int Ed Engl. 2012 Jun 25;51(26):6516-20. doi: 10.1002/anie.201202583. Epub 2012 May 29.

62 Scholz B, Marschalek R Epigenetics and blood disorders.  Br J Haematol 158, 307-322.

61 Zeidler, L., Zimmermann, M., Möricke, A., Meissner, B., Bartels, D., Tschan, C., Schrauder, A., Cario, G., Goudeva, L., Jäger, S., Ratei, R., Ludwig, W.D., Teigler-Schlegel, A., Skokowa, J., Koehler, R., Bartram, C.R., Riehm, H., Schrappe, M., Welte, K., Stanulla, M. Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.  Haematologica. 2012, 97:402-9.

2011

60 Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Bäumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U, Koschmieder S, Büchner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Müller-Tidow C. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012 Mar 8;119(10):2346-57. Epub 2011 Dec 29.

59 Albers C, Illert AL, Miething C, Leischner H, Thiede M, Peschel C, Duyster J. An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis. Blood. 2011 Aug 25;118(8):2200-10.

58 Appel IJ, Gronwald W, Spang R. Estimating classification probabilities in high-dimensional diagnostic studies. Bioinformatics. 2011 Sep 15;27(18):2563-70. Epub 2011 Jul 22.

57 Eckert C, Flohr T, Koehler R, Hagedorn N, Moericke A, Stanulla M, Kirschner-Schwabe R, Cario G, von Stackelberg A, Bartram C, Henze G, Schrappe M, Schrauder A. Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia. 2011 Aug; 25(8):1305-13. doi 10.1038/leu.2011.89

56 Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011 Aug 28;17(9):1086-93. doi: 10.1038/nm.2415.

55 Greif PA, Eck SH, Konstandin NP, Benet-Pagès A, Ksienzyk B, Dufour A, Vetter AT, Popp HD, Lorenz-Depiereux B, Meitinger T, Bohlander SK*, Strom TM*.  * joint senior authors. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing.Leukemia. 2011;25:821-827

54 Greif PA, Yaghmaie M, Konstandin N, Ksienzyk B, Alimoghaddam K, Ghavamzadeh A, Hauser A, Graf A, Krebs S, Blum H, Bohlander SK. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia. 2011;25:1519-1522.

53 Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, Mulaw M, Thoene S, Dufour A, Pasalic Z, Schmidberger M, Schmidt M, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia. 2011;25:1639-1645.

52 Herold T, Jurinovic V, Mulaw M, Seiler T, Dufour A, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes Chromosomes Cancer. 2011;50:546-558.

51 Hof J, Krentz S, van Schewick C, Koerner G, Shalapour S, Rhein P, Karawajew L, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R. Mutations and deletions of the TP53 gene predict non-response and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011 Aug 10;29(23):3185-93. doi 10.1200/JCO.2011.34.8144

50 Konstandin N, Bultmann S, Szwagierczak A, Dufour A, Ksienzyk B, Schneider F, Herold T, Mulaw M, Kakadia PM, Schneider S, Spiekermann K, Leonhardt H, Bohlander SK. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia. 2011;25:1649-1652.

49 Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 152, 141-154. (2011).

48 Mulaw MA, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia. 2011 Nov 8. doi: 10.1038/leu.2011.307. [Epub ahead of print]

47 Nedelkova M, Maresca M, Fu J, Rostovskaya M, Chenna R, Thiede C, Anastassiadis K, Sarov M, Stewart AF. Targeted isolation of cloned genomic regions by recombineering for haplotype phasing and isogenic targeting. Nucleic Acids Res. 2011 Nov 1;39(20):e137. Epub 2011 Aug 18.

46 Pasalic Z, Greif PA, Jurinovic V, Mulaw M, Kakadia PM, Tizazu B, Fröhlich-Archangelo L, Bohlander SK. FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. Blood Cancer Journal. 2011; November; 1(11): e42.

45 Pfaffeneder T, Hackner B, Truss M, Münzel M, Müller M, Deiml CA, Hagemeier C, Carell T. The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl. 2011 Jul 25;50(31):7008-12. doi 10.1002/anie.201103899.

44 Schmitz G, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B, Mirkowska P, Tchinda J, Niggli FK, Stanulla M, Schrappe M, Schrauder A, Bornhauser BC, Bourquin JP. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011 Aug 18;118(7):1854-64. Epub 2011 Jun 13.

43 Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, Henze G, von Stackelberg A, Seeger K. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica. 2011 Nov; 96(11):1627-35. doi 10.3324/haematol.2011.047993

42 Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, Cario G, Cazzaniga G, Kulozik AE, Stanulla M, Schrappe M, Biondi A, Basso G, Bercovich D, Muckenthaler MU, Izraeli S. Gain-of-function mutations in interleukin-7 receptor-alpha (il7r) in childhood acute lymphoblastic leukemias. J Exp Med 2011;208:901-908

41 Steffen B, Knop M, Bergholz U, Vakhrusheva O, Rode M, Köhler G, Henrichs MP, Bulk E, Hehn S, Stehling M, Dugas M, Bäumer N, Tschanter P, Brandts C, Koschmieder S, Berdel WE, Serve H, Stocking C, Müller-Tidow C. AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood. 2011 Apr 21;117(16):4328-37. Epub 2011 Jan 18.

40 Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A. MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood. 2011 Aug; 118(7):1899-1902

39 Thalappilly S, Feng X, Pastyryeva S, Suzuki K, Muruve D, Larocque D, Richard S, Truss M, von Deimling A, Riabowol K, Tallen G. The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. PLoS One. 2011;6(6):e21065 doi 10.1371/journal.pone.0021065

38 Tickenbrock L, Klein HU, Trento C, Hascher A, Göllner S, Bäumer N, Kuss R, Agrawal S, Bug G, Serve H, Thiede C, Ehninger G, Stadt UZ, McClelland M, Wang Y, Becker A, Koschmieder S, Berdel WE, Dugas M, Müller-Tidow C; for the SAL (Study Alliance Leukemia) Group. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res. 2011 May;35(5):620-5. Epub 2010 Dec 22.

37 von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thöne S, Aberg E, Peschel C, Duyster J. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene. 2011 Feb 24;30(8):933-43. Epub 2010 Oct 25.

2010

36 Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. . Blood 2010 Apr 8.

35 Eberle I, Pless B, Jacobi M, Dingermann T, Marschalek R. Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells. Nucl Acids Res 38, 5384-5395.

34 Keller U, von Bubnoff N, Peschel C, Duyster J. Oncologist's/hematologist's view on the roles of pathologists for molecular targeted cancer therapy. J Cell Mol Med. 2010 Feb 16. [Epub ahead of print]

33 Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Döhner K, Dugas M, Klein HU, Döhner H, Ehninger G, Haferlach T. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia. 2010 Apr;24(4):798-805.

32 Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, Koehler R, Tolle G, Bandapalli OR, Breit S, Muckenthaler MU, Kulozik AE. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010, 24(12):2005-2013

31 Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene. 2010 Feb 4;29(5):739-51.

30 Marschalek R. Mixed lineage leukemias: roles in human malignancies and potential therapy. FEBS J 277:1822-1831.

29 Müller-Tidow C, Klein H-U, Hascher A, Isken F, Tickenbrock L, Thoennissen N, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, zur Stadt U, Koschmieder S, Seidl M, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M and Serve H. Profiling of Histone H3 lysine 9 trimethylation levels predicts Transcription Factor Activity and Survival in Acute Myeloid Leukemia. Blood. 2010; 116(18):3564-71.

28 Paschka P, Schlenk R.F, Gaidzik V.I, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst H-A, Germing U, Döhner H, Döhner K. IDH1 and IDH2 Mutations are Frequent Genetic Alterations in Acute Myeloid Leukemia (AML) and Confer Adverse Prognosis in Cytogenetically Normal AML with NPM1 Mutation without FLT3-ITD. J Clinic Oncol. 2010;Jun 21 [Epub ahead of print].

27 Rawat VP, Arseni N, Ahmed F, Mulaw MA, Thoene S, Heilmeier B, Sadlon T, D'Andrea RJ, Hiddemann W, Bohlander SK, Buske C, Feuring-Buske M. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2010;107:16946-16951

26 Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, Hagemeier C, Stanulla M, Schrappe M, Ludwig WD, Karawajew L, Ratei R. CD11b is a therapy-resistance and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood. 2010 Mar 12; [Epub ahead of print]. doi 10.1182/blood-2009-10-247585

25 Von Bubnoff N, Duyster J. Chronic myelogenous leukemia: treatment and monitoring. Dtsch Arztebl Int. 2010 Feb;107(7):114-21.

24 Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Bührer C. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death.  Pediatr Res. 2010 Jan;67(1):35-41.

23 Wichmann C, Becker Y, Chen-Wichmann L, Vogel V, Vojtkova A, Herglotz J, Moore S, Koch J, Lausen J, Mäntele W, Gohlke H, Grez M. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. Blood. 2010 Jul 29;116(4):603-13.

22 Wichmann C, Grez M, Lausen J. Molecular targeting of leukemic transcription factors: Strate-gies for RUNX1/ETO. Curr Drug Targets. 2010 Sep;11(9):1181-91. Review.

21 Wiebusch L and Hagemeier C. p53- and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress. Oncogene 2010 Apr 12. [Epub ahead of print]

2009

20 Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Köhler G, Duyster J, Berdel WE, Müller-Tidow C, Serve H, Sargin B; Study Alliance Leukemias. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood. 2009 Nov 5;114(19):4197-208.

19 Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009 Apr 23;113(17):3889-90.

18 Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41.

17 Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med. 2009 Aug 31;206(9):1957-70.

16 Haas SC, Huber R, Gutsch R, Kandemir JD, Cappello C, Krauter J, Duyster J, Ganser A, Brand K. ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling modules. Br J Haematol. 2009 ; 148(5):777 - 790

15 Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro. Br J Haematol. 2009 Mar;144(6):865-74.

14 Kawamata N, Ogawa S, Seeger K, Kirschner-Schwabe R, Huynh T, Chen J, Megrabian N, Harbott J, Zimmermann M, Martin Schrappe M, Bartram CR, Koeffler HP. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol. 2009 Jun; 34(6):1603-1612. doi 10.3892/ijo_00000290

13 Lin YH, Kakadia PM, Chen Y, Li YQ, Deshpande AJ, Buske C, Zhang KL, Zhang Y, Xu GL, Bohlander SK. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood. 2009 Jul 16;114(3):651-8. Epub 2009 May 14.

12 Liu S, Breit S, Danckwardt S, Muckenthaler MU, Kulozik AE:Downregulation of Notch signalling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol 88: 613 - 621, 2009 Epub 2008 Dec 5.

11 Lueth M, Wronski L, Giese A, Kirschner-Schwabe R, Pietsch T, von Deimling A, Henze G, Kurtz A, Driever PH. Somatic mitochondrial mutations in pilocytic astrocytoma. Cancer Genet Cytogenet. 2009 Jul; 192(1):30-35.

10 Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009 Oct 20;27(30):5031-8. Epub 2009 Sep 14.

9 Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009 Nov 20;27(33):5580-6. Epub 2009 Oct 26.

8 Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009 Apr 1;15(7):2238-47. Epub 2009 Mar 10.

7 Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, Werft W, Breit S, Liu S, Engel F, Wittmann A, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Bartram CR, Radlwimmer B, Muckenthaler MU, Lichter P, Kulozik AE:High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood, 2009; 114: 1053-1062.

6 Thoene S, Rawat VP, Heilmeier B, Hoster E, Metzeler KH, Herold T, Hiddemann W, Gökbuget N, Hoelzer D, Bohlander SK, Feuring-Buske M, Buske C. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 2009 Apr;23(4):649-55. Epub 2009 Jan 22.

5 Trentin L, Girodan M, Dingermann T, Basso G, te Kronnie G, Marschalek R (2009). Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol 83, 406-419.

2008    

4 Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene. 2008 Jul 17;27(31):4380-4.

3 Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica. 2008 Nov;93(11):1718-22.

2 Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland M-C, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK*, Buske C*. An 86 probe set gene expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193-201. (*Both authors contributed equally.)

1 Teichler S, Schlenk RF, Strauch K, Hagner NM, Ritter M, Neubauer A. Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. Haematologica. 2008 Jul; 93(7):1105-7.